Optech Biotech

Be an innovative, research center of excellence fully exploiting aptamer and other biological technologies, staffed by committed, highly-qualified scientific experts providing new and better solutions to global clients. Push DNA aptamer-related diagnostic and therapeutic technologies into the marketplace

Shop Aptamers

Management/Staff

John G. Bruno, Ph.D.,
Senior Scientist & Chief Technology Officer, has over 28 years of experience in DNA aptamer development, immunology, and microbiology, as well as biological warfare agent, and foodborne and waterborne pathogen detection. He has been highly successful in obtaining federal grants, has authored > 70 peer-reviewed research journal articles, two book chapters and an edited book on such diverse topics in molecular recognition as detection of biowarfare agents and E. coli O157:H7 by immunomagnetic-electrochemiluminescence (IM-ECL), detection of toxic metal ions by ligand-capture ECL, and development and use of DNA aptamers for detection of organic pollutants, foodborne pathogens and biowarfare agents. Dr. Bruno is also the inventor on 13 patents.
Adrian Garcia,
Director of Products, has over 13 years of experience in Biotechnology, including development and sales of antibodies and sales of aptamers, and Microbiology. As the manager of aptamer sales he has directed clients to the best aptamer solution for their needs and for the past 3 years has overseen the implementation of aptamer sales. As a food safety expert, he has assisted food manufacturers with lab set up and auditing, knows federal regulations, and has assisted the development of and implemented USDA protocols. He has developed standards used for labs to obtain accreditation by governmental agencies to monitor Select Agents like C. botulinum and its toxins and to participate in the export of US agriculture products around the world. He is an expert in most areas of food microbiology and has developed the technical standards and training programs for laboratories across the US. He has expert knowledge in dealing with pathogenic E. coli, including non-O157 strains, Salmonella, Genus Listeria, Listeria monocytogenes, Campylobacter spp., and various quality indicator organisms like Aerobic and Anaerobic organisms, Lactic Acid Bacteria, Coliform, and more.

OTC BioTech OVERVIEW

In the Fall of 2002, Operational Technologies Corporation’s (OpTech) managerial staff met to discuss establishing a biotechnology division. As part of these discussions, John G. Bruno, PhD, proposed to leverage the Small Business Innovation Research (SBIR) process to obtain government funding for aptamer research in the proposed division. OpTech concurred with this strategy and established a biotechnology division naming Dr. Bruno as the division’s Senior Scientist/Chief Technology Officer (CTO).

Using the SBIR process, proposals exploring the use of aptamers in both diagnostic and therapeutic arenas were submitted to government agencies. In 2003, the first SBIR award was received from the National Science Foundation along with four additional SBIR awards from other government sources. In April of 2004, OTC Biotechnologies (OTC BioTech) was created as a fully-owned OpTech subsidiary and R&D center to conduct biotechnology research using aptamers.

Dr. Bruno receives 2011 Tibbetts Award in Washington, DC on behalf of Operational Technologies Corp. Biotechnology Division or OTC BioTech

OTC Biotech’s aptamer research and development was recognized recognized by selection as one of the winners of the 2011 Tibbetts Award in recognition of SBA unique contributions as a model of excellence for the SBIR Program.  Companies selected for this national award are recognized as having provided outstanding SBIR leadership.

FREE PDF

Development of DNA Aptamers to a Foot-and-Mouth Disease Peptide for Competitive FRET-Based Detection View PDF

 

Discrimination of Recombinant from Natural HumanGrowth Hormone Using DNA Aptamers View PDF